SCHEMBL2380291

SCHEMBL2380291

NC(=S)Nc1nnc(-c2ccccc2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.58
RAB9A P51151 8/20 0.58
SMN1; SMN2 Q16637 3/20 0.54
KDM4E B2RXH2 3/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA4 P22748 1/20 0.53
CA5A P35218 1/20 0.53
CA5B Q9Y2D0 1/20 0.53
CSNK2A2 P19784 1/20 0.50
CSNK2A1 P68400 1/20 0.50
RXFP1 Q9HBX9 1/20 0.49
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
TP53 P04637 2/20 0.48
USP2 O75604 1/20 0.48
GFER P55789 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8142656 0.81 NPC1 (0.52) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL3828303 0.79 NPC1 (0.71) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL9893004 0.76 CSNK2A2 (0.74) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL18788945 0.76 NPC1 (0.67) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL3334264 0.76 CA1 (0.61) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL8136698 0.75 NPC1 (0.50) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL11480689 0.75 CSNK2A2 (0.83) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL6215399 0.74 NPC1 (0.60) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL12015939 0.74 NPC1 (0.73) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL2421423 0.73 KDM4E (0.75) NPC1RAB9ASMN1; SMN2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170037016-A1 GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBVIE DEUTSCHLAND (DE) 2017-02-09 US disclosed
US-9475782-B2 Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors AbbVie Deutschland GmbH & Co. KG (DE) 2016-10-25 US disclosed
US-20130324537-A1 GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBOTT LABORATORIES (US) 2013-12-05 US disclosed
US-8481576-B2 Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors ABBOTT GMBH & CO. KG (DE) 2013-07-09 US disclosed
US-8431604-B2 Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors ABBOTT GMBH & CO. KG (DE) 2013-04-30 US disclosed
US-20110237589-A1 GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2011-09-29 US disclosed
US-20070299074-A1 Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130324537-A1 GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, GRM5, TAAR5 NPC1 2968/4885RAB9A 1420/4885SMN1; SMN2 1082/4885
US-20170037016-A1 GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, GRM5, GRK5 NPC1 3179/4885RAB9A 1428/4885SMN1; SMN2 1033/4885
US-20070299074-A1 Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors HTR5A, GRM5, TAAR5 NPC1 2968/4885RAB9A 1420/4885SMN1; SMN2 1082/4885
US-20110237589-A1 GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, GRM5, TAAR5 NPC1 2968/4885RAB9A 1420/4885SMN1; SMN2 1082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.